We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genomic Health to Unveil Oncotype DX Study Results at ASCO
Read MoreHide Full Article
Global cancer research company Genomic Health, Inc. will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago. The results represent data pertaining to multiple tumor types including invasive breast, ductal carcinoma in situ (DCIS), prostate and renal cancer.
Notably, Genomic Health’s Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions.
At the presentation, the company plans to present the SEER study of breast cancer based on recurrence score results, impact of the DCIS score adjusting for clinico-pathological features and performance of the 21-gene assay in HR+, HER2- invasive breast cancer.
Additionally, clinical outcomes of ER+ HER2-negative breast cancer, validation of the 16-gene Recurrence Score in stage III patients, analysis of intermediate-to-high genomic risk of HER2-negative early breast cancer, a 17-gene panel for prediction of adverse surgical pathology and finally association of risk of clinical recurrence and prostate cancer death with a 17-gene GPS value are going to be presented.
Per management, Genomic Health’s flagship product, the Oncotype DX Breast Recurrence Score analyses the recurrence in invasive breast cancer and chemotherapy benefit. Additionally, the Oncotype DX Breast DCIS Score predicts the probability of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score predicts disease aggressiveness and further clarifies the current and future risks of cancer prior to treatment intervention. Latest data provided by the company shows that with more than 750,000 patients tested in over 90 countries, the Oncotype DX line of tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment.
According to a Market Research Store report, the cancer diagnostics is poised to reach a worth of $128.6 billion in 2020, at a CAGR of 7.6%. Given the rising incidence of cancer and expenditure involved in the treatment procedures, Genomic Health continues to make consistent efforts to address the issue of cancer overtreatment.
Notably, over the last three months, Genomic Health has been trading above the Zacks categorized Medical - Biomedical and Genetics industry. As per the latest share price movement, the company has gained 2.4% over the past three months, compared to the 8.6% decline of the broader industry. This is because the company continues to make significant progress with its suite of cancer tests across the globe.
Zacks Rank & Key Picks
Genomic Health currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 10% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 80%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30% (last 3–5 years of actual earnings). The stock added roughly 8.3% over the last three months.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Genomic Health to Unveil Oncotype DX Study Results at ASCO
Global cancer research company Genomic Health, Inc. will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago. The results represent data pertaining to multiple tumor types including invasive breast, ductal carcinoma in situ (DCIS), prostate and renal cancer.
Notably, Genomic Health’s Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions.
At the presentation, the company plans to present the SEER study of breast cancer based on recurrence score results, impact of the DCIS score adjusting for clinico-pathological features and performance of the 21-gene assay in HR+, HER2- invasive breast cancer.
Additionally, clinical outcomes of ER+ HER2-negative breast cancer, validation of the 16-gene Recurrence Score in stage III patients, analysis of intermediate-to-high genomic risk of HER2-negative early breast cancer, a 17-gene panel for prediction of adverse surgical pathology and finally association of risk of clinical recurrence and prostate cancer death with a 17-gene GPS value are going to be presented.
Per management, Genomic Health’s flagship product, the Oncotype DX Breast Recurrence Score analyses the recurrence in invasive breast cancer and chemotherapy benefit. Additionally, the Oncotype DX Breast DCIS Score predicts the probability of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score predicts disease aggressiveness and further clarifies the current and future risks of cancer prior to treatment intervention. Latest data provided by the company shows that with more than 750,000 patients tested in over 90 countries, the Oncotype DX line of tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment.
According to a Market Research Store report, the cancer diagnostics is poised to reach a worth of $128.6 billion in 2020, at a CAGR of 7.6%. Given the rising incidence of cancer and expenditure involved in the treatment procedures, Genomic Health continues to make consistent efforts to address the issue of cancer overtreatment.
Notably, over the last three months, Genomic Health has been trading above the Zacks categorized Medical - Biomedical and Genetics industry. As per the latest share price movement, the company has gained 2.4% over the past three months, compared to the 8.6% decline of the broader industry. This is because the company continues to make significant progress with its suite of cancer tests across the globe.
Zacks Rank & Key Picks
Genomic Health currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 10% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 80%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30% (last 3–5 years of actual earnings). The stock added roughly 8.3% over the last three months.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>